Profit taking στα ευρωπαϊκά χρηματιστήρια

Με μικτά πρόσημα ολοκληρώθηκε η πρώτη συνεδρίαση της εβδομάδας στα ευρωπαϊκά χρηματιστήρια, όπου παρά τα κέρδη που κατέγραφαν τα περισσότερα από αυτά στο πρώτο μισό της διαπραγμάτευσης βρέθηκαν σε αρνητικό έδαφος στο δεύτερο μισό αυτής, με τους επενδυτές να προβαίνουν σε profit taking μετά την άνοδο της προηγούμενης εβδομάδας.

Στην Γερμανία, το εμπορικό ισοζύγιο για τον μήνα Ιούλιο διαμορφώθηκε στα 15,9 δισ. ευρώ έναντι εκτιμήσεων 18,0 δισ. ευρώ και 18,7 δισ. ευρώ τον προηγούμενο μήνα.

Στην Ελβετία, η οικονομία στο δεύτερο τρίμηνο δεν αναπτύχθηκε με τους οικονομολόγους να εκτιμούσαν ανάπτυξη 0,1% έναντι ανάπτυξης 0,3% το προηγούμενο τρίμηνο, ενώ σε ετήσια βάση το ΑΕΠ πραγματοποίησε αύξηση 0,5% (σύμφωνα με τις εκτιμήσεις) έναντι αύξησης 1,5% το προηγούμενο έτος.

Στην Ισπανία, οι άνεργοι αυξήθηκαν κατά 24.000 έναντι εκτιμήσεων για μείωση 21.300 και μείωσης 11.000 τον Αύγουστο.

Ο δείκτης Eurostoxx 600 έκλεισε στις 458,10μονάδες με οριακές απώλειες 0,01%.

Στην Φρανκφούρτη ο δείκτης DAX έκλεισε στις 15.821,25 μονάδες με απώλειες 0,12%, παραμένοντας με σήμα neutral, με την αντίσταση να βρίσκεται στις 16,144 μονάδες και την στήριξη στις 15.777 μονάδες.

Μεγαλύτερη άνοδος

Μεγαλύτερη πτώση

Στο Λονδίνο ο δείκτης FTSE 100 έκλεισε στις 7.451,90 μονάδες με απώλειες 0,17%, παραμένοντας με σήμα neutral, με την αντίσταση να βρίσκεται στις 7.531 μονάδες και την στήριξη στις 7.262 μονάδες.

Μεγαλύτερη άνοδος

Μεγαλύτερη πτώση

Στο Παρίσι ο δείκτης CAC 40 έκλεισε στις 7.279,51 μονάδες με απώλειες 0,24%, παραμένοντας με σήμα neutral, με την αντίσταση να βρίσκεται στις 7.438 μονάδες και την στήριξη στις 7.167 μονάδες.

Μεγαλύτερη άνοδος

Μεγαλύτερη πτώση

Recommendations

Telefonica: Berenberg readjusts its opinion and goes from selling to neutral on the stock. The target price is lowered from EUR 2.00 to EUR 1.80.

GSK: Barclays analyst Emily Field maintains his Neutral opinion on the stock. The target price remains unchanged at GBX 1450.

Airbus: Analyst Chloe Lemarie from Jefferies research gives the stock a Neutral rating. The target price continues to be set at EUR 130.

Air France-KLM: Barclays analyst Andrew Lobbenberg maintains his Buy rating on the stock. Previously set at EUR 2.60, the target price has been raised to EUR 26.00.

Ashmore Group: JPMorgan on Monday restarted coverage of Ashmore Group (ASHM.L) with an underweight rating and a price target of 1.76 pounds sterling. As of afternoon trading in London, shares of the asset management group lost nearly 1%.

Hammerson: Morgan Stanley on Monday upgraded Hammerson (HMSO.L, HMN.JO) to overweight from equal weight and increased the price target to 0.36 pound sterling from 0.27 pound. The UK-based real estate developer’s stock was up almost 3% in afternoon trading.

ENI: Giacomo Romeo from Jefferies retains his positive opinion on the stock with a Buy rating. The target price is unchanged at EUR 18.

Εταιρικά νέα

Nestle said it has sold its Palforzia peanut-allergy treatment business to biopharmaceutical company Stallergenes Greer. The Swiss consumer-goods company said Monday that it will receive milestone payments and royalties from Stallergenes Greer. The deal was closed upon signing, Nestle said. The sale allows Nestle’s health-science operations to focus on its core strengths and key growth drivers, the unit’s Chief Executive Greg Behar said. Nestle last year said that it would conduct a strategic review of Palforzia after a slower-than-expected adoption by patients and healthcare professionals.

BMW continues to see good demand for premium cars despite the generally gloomier economic environment, and expects positive order backlog through the end of the year, the car maker’s Chief Financial Officer Walter Mertl said in an interview. In the first quarter, orders in Europe were still slightly lower than the previous year, but they have been rising into the double digits since April, and that was also the case in June, July and August, the executive said. As a result, the group’s order backlog in Europe also remains good, and the total order backlog is currently slightly above 2022 levels.

“Our order backlog will comfortably carry us to the end of 2023,” said Mertl. BMW is getting tailwind especially from high demand for electric vehicles, and new-generation cars are expected to improve the overall profitability of the company’s electric business from 2025, according to the executive. “With the introduction of the Neue Klasse, we expect margins of electric vehicles and those of combustion-engine vehicles to gradually converge,” Mertl said. Whether this margin parity is reached in 2027, 2028 or 2029 will depend among other things on the ramping-up of new electric vehicles, Mertl said. “Ultimately, it’s the customer who decides.” At present, electric cars are still more expensive than combustion-engine cars due to battery costs.

Wizz Air Holdings carried 6.1 million passengers in August compared with 5 million for the same month of 2022. The Central and Eastern European low-cost airline said Monday that for the rolling 12-month period, it carried 56.6 million passengers compared with 39.5 million a year before. Load factor–a measure of how full a plane is–was 94.1% in the month, compared with 90.5% a year prior.

AstraZeneca said its Calquence product has been approved in China for the treatment of adults with leukaemia. The Anglo-Swedish pharma giant said Monday the product has been approved for the treatment of patients with chronic lymphocytic leukaemia, or CLL–the most prevalent type of leukaemia across the globe–or small lymphocytic lymphoma, or SLL, assuming they have received at least one prior therapy. The approval by the National Medical Products Administration was based on positive results from two clinical trials, one global and one local. The latter trial showed an 83.3% overall response rate in Chinese patients treated with Calquence. Calquence is approved for the treatment of CLL and SLL in the U.S., CLL in the European Union and other countries around the world, and approved in Japan for relapsed CLL and SLL.

Advanced Medical Solutions Group warned that its financial performance for 2023 will be affected due to the uncertainty around royalty stream and the higher destocking of its LiquiBand product in the U.S. The U.K. surgical and wound-care specialist said Monday that revenue for the year is now expected to be in the 124 million pounds to 127 million pounds ($156.1 million to $159.9 million) range. Adjusted pretax profit is expected to be in the GBP25 million to GBP27 million range. The company said Organogenesis–a company with which it has a patent-licensing agreement–announced that changes to U.S. reimbursement coverage for the treatment of diabetic foot ulcers and venous leg ulcers created uncertainty regarding the revenue outlook for some of its key products, including those using AMS patents. The company said that as Organogenesis has withdrawn guidance, and that it has no control or insight into its sales, it was unable to quantify the financial effect on AMS at this stage. It added it believed it was prudent to remove this royalty in its entirety from fourth quarter guidance onward. “Reflecting the board’s confidence, with the exception of the adjustment to the Organogenesis royalty, guidance for future years remains unchanged,” it said.

Conroy Gold and Natural Resources said it has found additional gold drilling targets after deep overburden sampling at the Longford-Down Massif joint venture in Northern Ireland. The London-listed Ireland and Finland-focused mining company said Monday that 500 samples in deep overburden sampling returned values of 10 parts per billion gold, with two samples showing over 400 ppb gold. As a result of the sampling, new drilling targets have been identified, including four new anomalous gold areas near the newly discovered Creenkill gold target in Northern Ireland. The company said it has completed 6,000 metres drilling to date in phase 1 of the joint venture programme with Demir Export. “This deep overburden programme has substantially raised the prospectiveness of each of the five areas surveyed. The collection of over 1,500 samples and resultant data has yielded extensive information for follow up drilling which we will pursue in partnership with Demir Export,” Chairman Richard Conroy said.

Belvoir said its pretax profit and revenue both rose despite challenging market conditions, that it is confident in meeting its full-year expectations, and hiked its dividend. The U.K. property-letting company said Monday that first-half pretax profit rose to 4.4 million pounds ($5.5 million), from GBP4.0 million a year prior. This reflects both resilience in the franchise business model and a strong lettings market performance, and a decline in administrative expenses and finance costs, the company said. Revenue increased to GBP15.9 million from GBP15.4 million, reflecting a small slip in revenue from the property franchise division, offset by increased management-service fees and financial-services revenue. The company said its confidence in meeting its expectations for the full year were underpinned by its current pipeline of agreed sales, the level of written mortgage business, continued excess demand for rental properties and incremental revenue from two recent acquisitions. It didn’t provide any financial expectations. The board declared an interim dividend of 5.0 pence a share, up from 4.0 pence.

ACQUIRER: Mitie Group, a U.K. outsourcing company.

TARGET: JCA Engineering, a U.K.-based critical environment project designer and principal contractor.

PRICE: A maximum cash consideration of 31.5 million pounds ($39.7 million). The company will pay an initial GBP21 million pounds with deferred payments of up to GBP10.5 million over three years linked to performance.

FINANCING: Acquisition to be funded from Mitie’s existing facilities.

RATIONALE: The transaction follows Mitie’s strategy to invest in high-growth, high-margin companies which enhance its projects capabilities in the energy-efficiency, office-fitouts and critical-environments growth areas.

Τα παραπάνω εκφράζουν προσωπικές απόψεις, και σε καμία περίπτωση δεν αποτελούν προτροπή για αγορά, πώληση ή διακράτηση οποιασδήποτε κινητής αξίας.